Work

Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.8021

Authors: Andrzej J. Jakubowiak, Agnes Benedict, Sumeet Panjabi, Ivan Houisse, Marco Campioni, Andromachi Giannopoulou, Sanjay Aggarwal, Rafael Fonseca

Institutions: University of Chicago Medical Center, Amgen (United States), Amgen (Switzerland), Mayo Clinic in Arizona

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892083382

Cites:

Cited by: 1

Related to: 10